A filing for anti-PD-1 drug Opdivo in lung cancer, plus three new licensing and acquisition deals, shows Bristol-Myers Squibb (BMS) has no intention of slowing its immuno-oncology drive.

Nearly 300 employees in Lawrenceville will lose their jobs as part of a pharmaceutical company's major cost-cutting measures, officials said.Bristol Myers Squibb will lay off at least 290 employees in ...